Core Viewpoint - INOVIO Pharmaceuticals, Inc. has announced a public offering of 14,285,715 shares of common stock and accompanying Series A and Series B warrants, priced at $1.75 per share, aiming to raise approximately $25 million before expenses [1][2]. Group 1: Offering Details - The public offering includes 14,285,715 shares of common stock and warrants to purchase an equal number of shares at an exercise price of $1.75 [1]. - The offering is expected to close on or about July 7, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase up to 2,142,857 additional shares and warrants at the public offering price [1]. Group 2: Financial Aspects - Gross proceeds from the offering are anticipated to be approximately $25 million, excluding underwriting discounts and commissions [2]. - The offering is being managed by Piper Sandler & Co. as the sole active book-running manager, with Oppenheimer & Co. Inc. as a passive bookrunner [2]. Group 3: Regulatory Information - A shelf registration statement for the offering was filed with the SEC on November 9, 2023, and was declared effective on January 31, 2024 [3]. - The offering is conducted through a written prospectus and prospectus supplement available on the SEC's website [3]. Group 4: Company Overview - INOVIO is focused on developing and commercializing DNA medicines aimed at treating HPV-related diseases, cancer, and infectious diseases [5]. - The company's technology is designed to optimize the design and delivery of DNA medicines that enable the body to produce its own disease-fighting tools [5].

Core Points - INOVIO, a biotechnology company, focuses on developing and commercializing DNA medicines for HPV-associated diseases, cancers, and infectious diseases [1][3] - The company will release its first quarter 2025 financial results on May 13, 2025, after market close [1] - A live conference call and webcast will follow the financial results release at 4:30 p.m. ET, including a Q&A session with analysts [1][2] Company Overview - INOVIO's technology is designed to optimize the design and delivery of DNA medicines that enable the body to produce its own disease-fighting tools [3] - The company aims to protect and treat individuals from HPV-related diseases and other infectious diseases through its innovative approach [3]